GILD

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

GILEAD SCIENCES INC

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

trader ai7

Equities

Large Cap

Mid Cap

Broad U.S. Equity ETFs

Politics

Markets

ETFs

FSLR

PLTR

SMCI

VRSN

금융 시장은 도널드 트럼프 대통령의 2024년 11월 5일 선거와 후속 취임식 이후로 변동성을 보이고 있다. 새로운 행정부 하에서 어떤 회사들이 급등했고, 어떤 회사들이 어려움을 겪었는지 살펴보겠다. 최고 실적: Benzinga Pro의 데이터에 의하면, 2024년 11월 5일 이후로 SPDR S&amp;P 500 ETF Trust(NYSE:SPY)에 포함된 여섯 개 회사가 30% 이상 수익률을 기록했다고 한다. 

트럼프 당선 이후 S&amp;P 500 주식 중 최고와 최악의 수익률

Gilead Sciences Inc.

Analyst Color

Biotech

Earnings

News

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ACLX

길리어드 사이언스(NASDAQ:GILD)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, 컨센서스 1.70달러를 초과했다고 보고한 이후의 일이다.

길리어드, 2025년 전망 상향 조정 및 HIV 예방을 위한 레나카파비르 출시 목표

GileadSciences.Shutterstock

After-Hours Center

길리어드 사이언스(NASDAQ:GILD)는 화요일(12일) 장 마감 후 4분기 재무 실적을 발표했다. 다음은 보고서의 주요 내용이다.

길리어드 사이언스, 4분기 실적 발표 이후 시간외 거래 4% 상승

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 5.24% on an annualized basis producing an average annual return of 13.4%. Currently, Gilead Sciences has a market capitalization of $138.43 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,262.82 today based on a price of $111.16 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743114612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Analysts' ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $116.27, with a high estimate of $140.00 and a low estimate of $84.00. Observing a 12.37% increase, the current average has risen from the previous average price target of $103.47. 
<img src="https://www.benzinga.com/files/images/story/2025/1743102080_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Gilead Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Gilead Sciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>Discovering Gilead Sciences: A Closer Look</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Gilead Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.4% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 23.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 9.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA excels beyond industry benchmarks, reaching 3.14%. This signifies efficient management of assets and strong financial health.
Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average at 1.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Gilead Sciences Stock

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 20% bullish and 80%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $108,790, and 13 are calls, for a total amount of $1,178,713.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $110.0 for Gilead Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Gilead Sciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Gilead Sciences's substantial trades, within a strike price spectrum from $100.0 to $110.0 over the preceding 30 days.
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743097625_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.6</td>
<td>$7.35</td>
<td>$7.5</td>
<td>$105.00</td>
<td>$162.0K</td>
<td>1.0K</td>
<td>433</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.55</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$105.00</td>
<td>$150.0K</td>
<td>1.0K</td>
<td>217</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$7.15</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$105.00</td>
<td>$145.7K</td>
<td>1.0K</td>
<td>812</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.1</td>
<td>$6.95</td>
<td>$6.98</td>
<td>$105.00</td>
<td>$145.0K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.75</td>
<td>$5.6</td>
<td>$5.75</td>
<td>$107.00</td>
<td>$115.0K</td>
<td>104</td>
<td>701</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Gilead Sciences</h3>
<ul>
<li>Currently trading with a volume of 2,915,168, the GILD's price is up by 1.67%, now at $111.09. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Expert Opinions on Gilead Sciences</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $131.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Gilead Sciences, targeting a price of $130. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Gilead Sciences, which currently sits at a price target of $132. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Gilead Sciences, which currently sits at a price target of $126. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Gilead Sciences, maintaining a target price of $140. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Gilead Sciences, targeting a price of $130. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

A Closer Look at Gilead Sciences's Options Market Dynamics

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $120 to $130.

Price Target

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $130

The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally.
The life sciences industry, a key pillar of the UK&#8217;s economic strategy, could struggle to attract investment unless payment rates are adjusted.
Last week, the government <a href="https://www.abpi.org.uk/media/news/2025/march/uk-set-to-demand-a-third-of-pharmaceutical-company-revenue-in-second-half-of-2025/" target="_blank" rel="noreferrer noopener">proposed</a> raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies&#8217; National Health Service (NHS) sales in the second half of 2025.
The payment rate is the revenue companies must hand back to the government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk&#8217;s Membership After 2 Years Of Suspension</a>
UK pharmaceutical leaders from Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Boehringer Ingelheim, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>), Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) and UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) point to the challenges to investing in the U.K.
The pharmaceutical sector <a target="_blank" href="https://www.abpi.org.uk/media/news/2025/march/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders/" rel="noreferrer noopener">contributes</a> over 17.6 billion pounds ($22.76 billion) directly to the U.K. economy, with an additional 45 billion generated through research and development spillovers.
However, companies argue that growth is being stifled due to escalating mandatory payments. Under the current system, firms must pay between 23.5% and 35.6% of their branded medicine sales revenue to the NHS. This is significantly higher than other European nations, where comparable rates range from 5.7% to 9%, ABPI writes.
The ABPI report highlights that while the UK once led in medicine availability, it has slipped to ninth place in Europe over the past decade. One year after launch, medicine usage in England is only 52% of the average of comparable nations, rising to 62% after five years.
Additionally, the UK has dropped from fourth to tenth in global rankings for phase 3 clinical trials, lagging behind Spain, Germany and Italy.
Investment in UK pharmaceutical research has also declined, with the country&#8217;s share of global R&amp;D investment falling from 7.3% to 5.7% in just three years.
This marks the fastest decline of any European G7 nation. Meanwhile, NHS funding has grown by 33% in real terms over the past decade, but spending on branded medicines has been capped at annual growth rates between 1.1% and 2%, declining by 11% when adjusted for inflation.
The industry and government have long collaborated on agreements to ensure NHS access to medicines.
The latest, the Voluntary Scheme for Branded Medicines, Pricing, Access, and Growth (VPAG), was intended to realign UK payment rates with international standards. While rates for newer medicines briefly dropped to 15.1% in 2024, they surged again in 2025 to 23.5% for newer medicines, with companies still paying 10.6%-35.6% for older products.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44436766/is-freeport-mcmorans-us-based-footprint-an-advantage-analyst-upgrades-stock-amid-copper-import-tariff-risk" target="_blank" rel="noreferrer noopener">Is Freeport-McMoRan&#8217;s US-Based Footprint An Advantage? Analyst Upgrades Stock Amid Copper Import Tariff Risk</a></li>
</ul>
Photo: Shutterstock

Government

Eurozone

AMGN

BIIB

DSNKY

RHHBY

UCBJF

UCBJY

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

WIIM

Gilead Sciences shares are trading lower after reports indicating the Trump administration is considering cuts to domestic HIV prevention programs.

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock is trading lower during the premarket trading session on Wednesday.
According to a Tuesday report in the Wall Street Journal, the Health and Human Services Department (HHS) is considering substantial reductions in federal funding for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">domestic HIV prevention</a>.
According to people familiar with the matter, the WSJ reports that the plans could be announced within a day. However, they are not final and could still be changed or canceled.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a>
The Centers for Disease Control and Prevention (CDC) has a department focused on preventing HIV and other infectious diseases. It provides funding for state and local programs, including HIV tracking, syringe services, and community outreach, the WSJ writes.
Meanwhile, the Trump administration is planning significant staff cuts at the CDC as part of a broader reorganization, according to WSJ sources. The agency's structure makes it vulnerable to such changes since no single law defines its mission or programs.
Mitchell Warren, executive director of HIV prevention group AVAC, says the CDC's pre-exposure prophylaxis (PrEP) program could be reduced or cut. Launched last fall as a pilot program, it provides free medication to help prevent HIV.
PrEP&nbsp;is used by people who are HIV-negative and at high risk of being exposed to HIV infection.
In 2021, the FDA approved ViiV Healthcare's Apretude, the first injectable form of PrEP <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">administered every two months</a>. ViiV Healthcare is owned by Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and Shinogi Ltd.
In 2023, the agency <a target="_blank" href="https://www.cdc.gov/nchhstp/budget-funding/index.html#cdc_program_funding_fund_by_cat-how-is-cdc-funding-used-for-hiv-viral-hepatitis-stis-tuberculosis-prevention" rel="noreferrer noopener">allocated</a> approximately $1.3 billion to combat HIV, viral hepatitis, sexually transmitted infections, and tuberculosis. Roughly 75% of those funds support state and local health departments, nonprofits, and other organizations engaged in disease prevention and outbreak response.
"No final decision on streamlining CDC's HIV Prevention Division has been made," the WSJ report <a target="_blank" href="https://www.wsj.com/health/healthcare/trump-administration-weighing-major-cuts-to-funding-for-domestic-hiv-prevention-8dcad39b" rel="noreferrer noopener">added</a>, citing the department's spokesman.
Gilead filed for regulatory approval of lenacapavir for PrEP (twice a year) last year and expects a potential <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention" rel="noreferrer noopener">commercial launch in 2025</a>.&nbsp;
Gilead also&nbsp;revealed that it is developing a once-yearly injectable formulation for lenacapavir. In its investor presentation, the company expects&nbsp;the pivotal Phase 3 pharmacokinetics study's first patient to be in 2025, and potential regulatory filings will <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">begin in late 2027</a>.
Price Action: At the last check on Wednesday, GILD stock was down 2.02% at $108 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44393734/siemens-to-slash-6000-jobs-as-demand-slows-in-germany-and-china" target="_blank" rel="noreferrer noopener">Siemens To Slash 6,000 Jobs As Demand Slows In Germany And China</a></li>
</ul>

Media

Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides

Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $436,483, and 4 are calls, amounting to $134,326.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $120.0 for Gilead Sciences over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale trades within a strike price range from $90.0 to $120.0 in the last 30 days. 
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742322647_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$8.35</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$100.00</td>
<td>$249.0K</td>
<td>0</td>
<td align="right">339</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.25</td>
<td>$15.4</td>
<td>$15.4</td>
<td>$120.00</td>
<td>$70.8K</td>
<td>27</td>
<td align="right">50</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.79</td>
<td>$2.67</td>
<td>$2.68</td>
<td>$110.00</td>
<td>$49.7K</td>
<td>2.8K</td>
<td align="right">82</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.97</td>
<td>$1.78</td>
<td>$1.78</td>
<td>$115.00</td>
<td>$40.6K</td>
<td>5.9K</td>
<td align="right">406</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$8.2</td>
<td>$8.0</td>
<td>$8.2</td>
<td>$100.00</td>
<td>$37.7K</td>
<td>0</td>
<td align="right">492</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 4,472,451, the GILD's price is up by 0.12%, now at $112.4. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
<h3>Professional Analyst Ratings for Gilead Sciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $129.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $140. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Gilead Sciences, targeting a price of $126. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Gilead Sciences, maintaining a target price of $130. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Gilead Sciences, which currently sits at a price target of $132. 
&#x2A; In a positive move, an analyst from Deutsche Bank has upgraded their rating to Buy and adjusted the price target to $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Unpacking the Latest Options Trading Trends in Gilead Sciences

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has risen 6.47% since its last report. The company recently reported that it has 22.58 million shares sold short, which is 1.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741895121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Gilead Sciences Gaining or Losing Market Support?

On Wednesday, Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) presented data from its HIV treatment portfolio and pipeline at the&nbsp;Conference on Retroviruses and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Opportunistic Infections&nbsp;(CROI 2025)</a>.
ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44273943/gilead-presents-new-hiv-treatment-and-cure-research-data-at-croi-2025-including-an-investigational" rel="noreferrer noopener">coinfection initiating treatment</a>.
<ul>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanhiv%2Farticle%2FPIIS2352-3018%252823%252900151-0%2Ffulltext&amp;esheet=54222729&amp;newsitemid=20250311386143&amp;lan=en-US&amp;anchor=Previously+reported+results&amp;index=3&amp;md5=10debf8f20cc3e5d6237cdbbcf58ee3a" target="_blank" rel="noreferrer noopener">Previously reported results</a> demonstrated the efficacy of both antiretroviral regimens.</li>
<li>The newly presented data shows that Biktarvy maintained high rates of HIV-1 (95.4%) and HBV (86.6%) virologic suppression, defined as HIV RNA &lt;50 copies/ mL and HBV DNA &lt;29 IU/ mL, respectively, in participants (n=89) following a switch to Biktarvy after 96 weeks of treatment with DTG+ F/TDF.</li>
<li>Study drug-related treatment-emergent adverse events were reported in 19% of participants and most were mild to moderate, with zero discontinuations due to TEAEs.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43673047/gilead-ups-2025-outlook-eyes-lenacapavir-launch-for-hiv-prevention" rel="noreferrer noopener">Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention</a>
At CROI 2025, the primary results of a Phase 2 study evaluating lenacapavir (LEN) with teropavimab (TAB) and zinlirvimab (ZAB) (LTZ) were presented.
<ul>
<li>The study met its primary endpoint: the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26.</li>
<li>The Week 26 data demonstrated the high efficacy of the LTZ regimen, with 96% of participants who received LTZ and 96% (n=26 of 27) who received SBR, remained virologically suppressed.</li>
<li>CD4 cell counts also increased from baseline to week 26 in both groups.</li>
<li>The most common AEs with LTZ were injection site reactions related to subcutaneous LEN administration.</li>
</ul>
The Phase 2a GS-US-382-5445 trial enrolled 20 South African cisgender women who had received antiretroviral therapy (ART) soon after acquiring HIV and were virologically suppressed for at least 12 months.
<ul>
<li>Participants received up to 10 oral doses of Gilead&#8217;s vesatolimod, every 2 weeks starting on day 0, plus IV infusions of broadly neutralizing antibodies (bNAbs) VRC07-523LS and CAP256V2LS, provided by the National Institutes of Health.</li>
<li>Results presented at CROI showed the treatment combination was generally well-tolerated with no treatment-related serious adverse events (TEAEs) reported.</li>
</ul>
Price Action: GILD stock is up 0.04% at $114.47 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44277627/ge-aerospace-doubles-down-on-us-manufacturing-with-1b-investment-details" target="_blank" rel="noreferrer noopener">GE Aerospace Doubles Down On US Manufacturing With $1B Investment: Details</a></li>
</ul>
Photo via Shutterstock

Gilead Presents New HIV Treatment And Cure Research Data

Macro Economic Events

Economics

Gilead Highlights Presentation Of HIV Data At CROI 2025

– Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 –
– Also at CROI: New PURPOSE 1 Data Showcasing Preference for Twice-Yearly Lenacapavir vs. Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.croiconference.org%2F&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=Conference+on+Retroviruses+and+Opportunistic+Infections+%28CROI+2025%29&amp;index=1&amp;md5=0fafdb2afddbf29a67a862e132e0e488">Conference on Retroviruses and Opportunistic Infections (CROI 2025)</a> and were also published today in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252825%252900405-2%2Ffulltext&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=The+Lancet&amp;index=2&amp;md5=c3f2c8a6aa1342e85f0988ce3b22c75b">The Lancet</a>. Data will support the future development of once-yearly lenacapavir for PrEP, for which Gilead plans to launch a Phase 3 study in the second half of 2025.
The Phase 1 study data showed that the two different formulations of once-yearly lenacapavir administered via intramuscular injection achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy observed in the Phase 3 <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Ffull-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=PURPOSE+1+trial&amp;index=3&amp;md5=fae50b34fe3d1937f06ea61a224ce2e6">PURPOSE 1 trial</a> (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04994509&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=NCT04994509&amp;index=4&amp;md5=9628ecf3bbd99007a00874c89ce08c7d">NCT04994509</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Fgilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=PURPOSE+2+trial&amp;index=5&amp;md5=e858a579f72e1e91233fc2a994376bef">PURPOSE 2 trial</a> (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04925752%3Fcond%3DHIV%26term%3Dpurpose%25202%26rank%3D1&amp;esheet=54222447&amp;newsitemid=20250311300348&amp;lan=en-US&amp;anchor=NCT04925752&amp;index=6&amp;md5=d78f50b34977573acad0d5f355c25638">NCT04925752</a>). The previously reported PURPOSE 1 and PURPOSE 2 data showed that twice-yearly subcutaneous lenacapavir demonstrated superiority at reducing HIV infections when compared to background HIV incidence (bHIV) and once-daily oral Truvada&#xAE; (emtricitabine 200mg and tenofovir disoproxil fumarate 300mg; F/TDF) in a broad and geographically diverse range of people.

Gilead Sciences Presented First Clinical Data For Its Investigational Once-Yearly Lenacapavir For HIV Prevention At CROI 2025 And Published In The Lancet

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup cut AvePoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) price target from $18 to $16. Citigroup analyst Fatima Boolani maintained a Neutral rating. AvePoint shares closed at $13.50 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AVPT/analyst-ratings">view this stock</a>.</li>
<li>BMO Capital boosted the price target for Protagonist Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) from $62 to $72. BMO Capital analyst Etzer Darout maintained an Outperform rating. Protagonist Therapeutics shares closed at $55.95 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/PTGX/analyst-ratings">view this stock</a>.</li>
<li>Stifel cut DarioHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) price target from $3.5 to $2. Stifel analyst David Grossman maintained a Buy rating. DarioHealth shares closed at $0.6710 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/DRIO/analyst-ratings">view this stock</a>.</li>
<li>Oppenheimer slashed the price target for OnKure Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) from $35 to $30. Oppenheimer analyst Matt Biegler maintained an Outperform rating. OnKure Therapeutics shares closed at $4.96 on Monday. <a href="https://www.benzinga.com/quote/OKUR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut the price target for Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) from $25 to $18. Mizuho analyst Robert Mosca maintained an Outperform rating. Venture Global shares closed at $8.95 on Monday. <a href="https://www.benzinga.com/quote/VG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) price target from $212 to $202. Barclays analyst Raimo Lenschow maintained an Overweight rating. Oracle shares settled at $148.79 on Monday. <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>WestPark Capital slashed SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) price target from $34 to $31. WestPark Capital analyst Casey Ryan maintained a Buy rating. SentinelOne shares closed at $18.17 on Monday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) price target from $30 to $25. B of A Securities analyst Michael Funk maintained a Buy rating. Asana shares closed at $16.68 on Monday.  <a href="https://www.benzinga.com/quote/ASAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity raised the price target for BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) from $3 to $4.75. Canaccord Genuity analyst Kingsley Crane maintained a Hold rating. BlackBerry shares settled at $4.19 on Monday. <a href="https://www.benzinga.com/quote/BB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) price target from $123 to $130. Morgan Stanley analyst Matthew Harrison maintained an Overweight rating. Gilead Sciences shares closed at $117.21 on Monday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Pre-Market Outlook

ASAN

AVPT

DRIO

OKUR

ORCL

PTGX

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $115.29, accompanied by a high estimate of $140.00 and a low estimate of $84.00. This upward trend is evident, with the current average reflecting a 12.71% increase from the previous average price target of $102.29.
<img src="https://www.benzinga.com/files/images/story/2025/1741698038_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Gilead Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$126.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$96.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$123.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$113.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gilead Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Gilead Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>About Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>A Deep Dive into Gilead Sciences's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 6.4% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 23.56%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 9.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.14%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.38, Gilead Sciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $123 to $130.

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $130

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $233,330, and 5 are calls, for a total amount of $272,215.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $125.0 for Gilead Sciences, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Gilead Sciences stands at 694.14, with a total volume reaching 1,574.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $70.0 to $125.0, throughout the last 30 days.
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741621544_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$29.8</td>
<td>$29.3</td>
<td>$29.5</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>1.0K</td>
<td>51</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.4</td>
<td>$1.16</td>
<td>$1.4</td>
<td>$116.00</td>
<td>$138.6K</td>
<td>91</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.75</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$110.00</td>
<td>$67.8K</td>
<td>255</td>
<td>118</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$120.00</td>
<td>$40.0K</td>
<td>2.4K</td>
<td>151</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$125.00</td>
<td>$31.5K</td>
<td>446</td>
<td>64</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>With a volume of 2,838,967, the price of GILD is up 1.24% at $118.87. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 45 days.</li>
</ul>
<h3>Professional Analyst Ratings for Gilead Sciences</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $111.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Deutsche Bank upgrades its rating to Buy with a revised price target of $120. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Gilead Sciences, maintaining a target price of $120. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Gilead Sciences, which currently sits at a price target of $90. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Gilead Sciences with a target price of $115. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $110. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Gilead Sciences's Options: A Look at What the Big Money is Thinking

Financial markets have been volatile since President&nbsp;Donald Trump&#8216;s <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">election on Nov. 5, 2024</a>, and subsequent inauguration. Which companies have surged under the new administration and which have struggled?
Best Performers: Six companies in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) have returned over 30% since Nov. 5, 2024, according to data <a href="https://pro.benzinga.com/dashboard">from Benzinga Pro.</a>
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) leads the pack, rocketing up 59.91% from $51.13 to $81.76. The Denver, Colorado-based company&#8217;s annualized return is over 184%. The retail investor darling has capitalized on AI trends and CEO Alex Karp&#8217;s support for Elon Musk&#8217;s government efficiency efforts, which he defended as a push to eliminate <a href="https://www.benzinga.com/markets/equities/25/02/43806845/palantir-ceo-alex-karp-backs-elon-musks-government-efficiency-efforts-calls-him-most-important-builder">fraud, waste, and abuse.</a>
According to Benzinga Edge, the company has momentum on its side, scoring a very high 99 out of 100, though it lags on key valuation metrics, indicating the stock could be overvalued.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/pltr"><img loading="lazy" decoding="async" width="1024" height="232" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-1024x232.png" alt="" class="wp-image-814893" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-1024x232.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-300x68.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-768x174.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM.png 1340w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
<ul>
<li>Unlock the rest of the BZ Edge Rankings and <a href="https://www.benzinga.com/quote/TPR">see how&nbsp;Tapestry Inc. stacks up</a></li>
</ul>
Five other stocks have returned 30% or more since Trump&#8217;s election victory:
<ul>
<li>Tapestry Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), up 49.66% (148.56% annualized).</li>
<li>Warner Bros Discovery Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), up 35.32% (105.68% annualized).</li>
<li>VeriSign, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>), up 33.19% (99.30% annualized).</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), up 33.32% (99.69% annualized).</li>
<li>Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), up 30.48% (91.19% annualized).</li>
</ul>
Worst Performers: Several other S&amp;P 500 companies have fared much worse since Trump prevailed in the November election.
Some poor performers have been impacted by Trump&#8217;s policies. First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), a manufacturer of solar panels, has seen its stock decline amid concerns about Trump&#8217;s support for fossil fuels. The Tempe, Arizona-based company&#8217;s shares have sunk 36.41% since Nov. 5, 2024.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/FSLR"><img loading="lazy" decoding="async" width="1024" height="230" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-1024x230.png" alt="" class="wp-image-814924" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-1024x230.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-300x67.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-768x173.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM.png 1316w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Benzinga Edge indicates the company may be undervalued at depressed valuations but does not fare well with its momentum and growth prospects.
Four other stocks round of the worst performers in the S&amp;P 500 since Trump&#8217;s win:
<ul>
<li>Iron Mountain Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) shares declined 34.47%.</li>
<li>ON Semiconductor Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) shares fell 35.71%.</li>
<li>FMC Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) shares tumbled 35.32%.</li>
<li>Celanese Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) shares sunk 39.6%.</li>
</ul>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44194357/markets-breathe-sigh-of-relief-as-february-jobs-data-shows-economy-not-falling-off-a-cliff-economist-says">Markets Breathe &#8216;Sigh Of Relief&#8217; As February Jobs Data Shows Economy &#8216;Not Falling Off A Cliff,&#8217; Economist Says</a></li>
</ul>
Disclaimer: The author owns shares of Warner Bros. Discovery at the time of publication.
Image created using artificial intelligence via Midjourney.

Best And Worst Performing S&P 500 Stocks Since Trump's Election Win

In the current session, the stock is trading at $116.29, after a 0.22% spike. Over the past month, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock increased by 21.08%, and in the past year, by 54.39%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1741359630_0.png" alt="Past Year Chart" />

<h3>Comparing Gilead Sciences P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology industry. Ideally, one might believe that Gilead Sciences Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741359630_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Gilead Sciences

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 5.67% on an annualized basis producing an average annual return of 13.79%. Currently, Gilead Sciences has a market capitalization of $144.34 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,300.17 today based on a price of $115.90 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741302909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years

B of A Securities analyst Tim Anderson maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Buy and raises the price target from $116 to $126.

B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $126

Press Releases

Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025

Contracts

Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications

Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results

Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 Dividend

U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

CTSH

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Morgan Stanley

B of A Securities

Wells Fargo

Oppenheimer

금융 시장은 도널드 트럼프 대통령의 <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election" target="_blank" rel="noopener" data-google-interstitial="false">2024년 11월 5일 선거</a>와 후속 취임식 이후로 변동성을 보이고 있다. 새로운 행정부 하에서 어떤 회사들이 급등했고, 어떤 회사들이 어려움을 겪었는지 살펴보겠다.
최고 실적: <a href="https://pro.benzinga.com/dashboard">Benzinga Pro의 데이터</a>에 의하면, 2024년 11월 5일 이후로 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)에 포함된 여섯 개 회사가 30% 이상 수익률을 기록했다고 한다.
팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)가 59.91% 상승하여 51.13달러에서 81.76달러로 급등하며 1위에 올랐다. 덴버, 콜로라도에 본사를 둔 이 회사는 연간 184% 이상의 수익률을 기록하고 있다. 소매 투자자들 사이에서 인기를 끌고 있는 팔란티어는 인공지능(AI) 트렌드를 활용하고 CEO 알렉스 카프가 일론 머스크의 정부 효율성 노력을 지지한 것을 통해 큰 주목을 받았다. 그는 이를 <a href="https://www.benzinga.com/markets/equities/25/02/43806845/palantir-ceo-alex-karp-backs-elon-musks-government-efficiency-efforts-calls-him-most-important-builder">사기, 낭비 및 남용을 없애려는 추진력</a>으로 방어했다.
벤징가 엣지에 따르면, 팔란티어는 100점 만점에 99점이라는 매우 높은 점수를 받아 모멘텀에서 유리한 위치에 있지만, 주요 가치 평가 지표에서는 뒤처져 있어 주식이 과대평가될 수 있음을 나타낸다.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/pltr"><img loading="lazy" decoding="async" class="wp-image-814893" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-1024x232.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-1024x232.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-300x68.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM-768x174.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07132016/Screenshot-2025-03-07-at-1.20.11-PM.png 1340w" alt="" width="1024" height="232" /></a></figure>
<ul>
<li>나머지 BZ 엣지 순위를 잠금 해제하고 <a href="https://www.benzinga.com/quote/TPR">태피스트리와의 비교를 확인하세요</a></li>
</ul>
트럼프의 선거 승리 이후 30% 이상 수익률을 기록한 다른 다섯 개 주식은 다음과 같다:
<ul>
<li>태피스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), 49.66% 상승 (연환산 148.56%).</li>
<li>워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), 35.32% 상승 (연환산 105.68%).</li>
<li>베리사인(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>), 33.19% 상승 (연환산 99.30%).</li>
<li>슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), 33.32% 상승 (연환산 99.69%).</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), 30.48% 상승 (연환산 91.19%).</li>
</ul>
최악의 실적: 트럼프가 11월 선거에서 승리한 이후 S&amp;P 500에 포함된 여러 회사들은 훨씬 더 나쁜 실적을 보였다.
일부 저조한 실적을 보인 회사들은 트럼프의 정책에 영향을 받았다. 퍼스트 솔라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)는 태양광 패널 제조업체로, 트럼프가 화석 연료를 지원하는 것에 대한 우려로 주가가 36.41% 하락했다. 이 회사의 주가는 2024년 11월 5일 이후로 36.41% 하락했다.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/FSLR"><img loading="lazy" decoding="async" class="wp-image-814924" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-1024x230.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-1024x230.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-300x67.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM-768x173.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/07133556/Screenshot-2025-03-07-at-1.35.52-PM.png 1316w" alt="" width="1024" height="230" /></a></figure>
벤징가 엣지에 따르면, 회사는 저평가된 가치에도 불구하고 모멘텀과 성장 전망이 좋지 않아 성과가 좋지 않다고 한다.
트럼프의 승리 이후 S&amp;P 500에서 최악의 실적을 기록한 네 개의 주식은 다음과 같다:
<ul>
<li>아이언 마운틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) 주식은 34.47% 하락했다.</li>
<li>온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) 주식은 35.71% 하락했다.</li>
<li>FMC 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) 주식은 35.32% 하락했다.</li>
<li>셀라니즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) 주식은 39.6% 하락했다.</li>
</ul>
추가 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44194357/markets-breathe-sigh-of-relief-as-february-jobs-data-shows-economy-not-falling-off-a-cliff-economist-says">2월 고용 데이터가 경제가 &#8216;벼랑 끝에서 떨어지지 않는다&#8217;고 보여주자 시장이 &#8216;안도감&#8217;을 표했습니다. 경제학자 발언</a></li>
</ul>
면책 조항: 작성자는 발행 시점에 Warner Bros. Discovery의 주식을 보유하고 있습니다.
이미지는 Midjourney를 통해 인공지능으로 생성되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

트럼프 당선 이후 S&P 500 주식 중 최고와 최악의 수익률

길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주식은 수요일 7% 이상 상승 마감했다. 이는 화요일 회사가 2024년 4분기 조정 EPS가 1.90달러로, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">컨센서스 1.70달러를 초과</a>했다고 보고한 이후의 일이다.
매출은 작년 대비 6% 증가한 75.7억 달러로, 컨센서스인 71.4억 달러를 초과했다. 이는 주로 HIV 부문, 종양학 및 간질환 부문의 매출 증가로 인한 것이며, 베클루리(Veklury) (렘데시비르) 매출 감소로 일부 상쇄되었다.
HIV 매출은 16% 증가하여 54.5억 달러에 달했으며, <a href="https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/GILD-Q424-Summary-of-Prepared-Remarks-11-February-2025.pdf" target="_blank" rel="noreferrer noopener">수요 증가, 더 높은 실현 가격 및 재고 동향의 긍정적 영향</a>이 주요 원인이었다.
빅타비(Biktarvy)의 분기 매출은 31.2억 달러에서 38억 달러로 증가했다.
간질환 매출은 7.19억 달러로 4% 증가했으며, 이는 리브델지(Livdelzi)의 강력한 출시와 HBV/HDV 수요 증가에 기인한 것이지만, 환자 시작 감소로 인한 HCV 매출 감소가 일부 상쇄되었다.
배당금: 길리어드 사이언스는 분기 현금 배당금을 2.6% 인상하여 <a href="https://www.benzinga.com/pressreleases/25/02/b43640030/gilead-sciences-announces-2-6-percent-increase-in-first-quarter-2025-dividend" target="_blank" rel="noreferrer noopener">0.79달러로</a> 발표했다.
또한 읽어보기: <a href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" target="_blank" rel="noreferrer noopener">길리어드, 덜 빈번한 예방 접종 희망을 제공하는 새로운 연간 HIV 주사제 발표</a>
가이던스: 길리어드은 2025년 조정 EPS를 7.70달러-8.10달러로 예상하며, 컨센서스는 7.58달러이다. 매출은 28.2억 달러-28.6억 달러로 예상하며, 이는 컨센서스 28.42억 달러를 상회한다.
&#8220;상업적 강점을 바탕으로, 우리는 2025년 여름에 HIV PrEP용 레나카파비르(lenacapavir)의 잠재적 출시를 계획하고 있다. 이는 HIV 예방 범위를 확장할 수 있는 독특한 기회를 제공한다&#8221; 고 길리어드의 회장 겸 CEO인 다니엘 오데이(Daniel O&#8217;Day)가 말했다.
파이퍼 샌들러는 길리어드의 목표 주가를 105달러에서 110달러로 상향 조정했으며, <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">비중 확대 등급은 변동 없음</a>을 유지했다. 분석가들은 올해 말 PrEP에서 레나카파비르의 상업적 출시와 몇 가지 중요한 후기 단계 결과 발표를 인용했다.
길리어드은 작년에 레나카파비르의 PrEP에 대한 규제 승인 신청서를 제출한 후, 여전히 2025년 상업적 출시 가능성을 기대하고 있다. 이는 회사가 PrEP 시장에서의 입지를 확보하고 환자 순응도를 개선하는 데 도움이 될 수 있다. 또한 2030년대 후반까지 HIV 리더십을 강화할 것이다.
골드만삭스는 길리어드이 레나카파비르 출시를 잘 준비하고 있다고 언급했다.
HIV 사업에 대해 골드만삭스의 애널리스트인 살빈 리히터(Salveen Richter)는 코멘트가 최근 투자자 행사와 대체로 일치했다고 전했다.
분석가는 카이트(Kite)와 트로델비(Trodelvy)에 영향을 미치는 경쟁으로 인해 종양학에서 어려움이 있다고 보지만, 아셀엑스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>)의 파트너십 치료제인 아니토셀(anito-cel)에 대한 긍정적인 전망을 유지하고, 트로델비의 확장을 주목하고 있다.
니덤의 애널리스트인 조셉 스트링거(Joseph Stringer)는 2025년에 가치를 주도할 두 가지 주요 이벤트가 있다고 보고한다: HIV 예방을 위한 레나카파비르의 출시 예상과 1차 전이성 삼중음성 유방암에 대한 트로델비의 3상 시험 업데이트이다.
애널리스트는 현재 수준에서 균형 잡힌 위험/보상으로 인해 길리어드에 대한 보유 등급을 유지하지만, 길리어드의 HIV 사업의 강력한 성과, 개선된 이익률, 레나카파비르의 매출 증가 잠재력에 대해 점점 더 낙관적으로 보고 있다.
가격 동향: 길리어드 사이언스의 주식은 수요일 7.46% 상승한 103.31달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43665455/te-connectivity-snaps-up-richards-manufacturing-for-2-3-billion-details" target="_blank" rel="noreferrer noopener">TE 커넥티비티, 리차드 제조사를 23억 달러에 인수</a></li>
</ul>
이미지 출처: Gilead Sciences
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 화요일(12일) 장 마감 후 4분기 재무 실적을 발표했다. 다음은 보고서의 <a href="https://www.benzinga.com/pressreleases/25/02/b43639858/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noopener">주요 내용이다.</a>
실적 세부 사항: 길리어드 사이언스는 애널리스트 컨센서스 예상치 1.70달러를 상회하는 주당 1.90달러의 분기 순이익을 발표했다. 분기 매출은 75억 6,000만 달러로 애널리스트 컨센서스 예상치 71억 3,000만 달러를 상회했으며 전년 동기 71억 1,000만 달러의 매출보다 증가했다.
<ul>
<li>2024년 4분기 총 제품 매출은 2023년 같은 기간에 비해 7% 증가한 75억 달러를 기록했다.</li>
<li>베클루리(Veklury)를 제외한 총 제품 매출은 2023년 같은 기간에 비해 13% 증가한 72억 달러로, 주로 HIV와 종양학 및 간 질환 분야의 매출 증가에 힘입어 증가했다.</li>
<li>2024년 4분기 비일반회계기준 제품 매출총이익률은 2023년 같은 기간의 86.1%에 비해 86.7%를 기록했다.</li>
<li>2024년 4분기 연구개발 비용은 2023년 같은 기간의 14억 달러에 비해 16억 달러로, 주로 포트폴리오 전반에 걸친 투자 및 임상 활동의 증가로 인해 증가했다.</li>
</ul>
대니얼 오데이(Daniel O&#8217;Day) CEO는 "길리어드는 2024년에 8%, 4분기에 전년 동기 대비 13%의 기본 비즈니스 제품 매출 성장을 기록하며 또 한 번 매우 강력한 연간 및 4분기 실적을 달성했다&#8221;고 말했다.
"이러한 상업적 강점을 바탕으로 2025년 여름에 HIV 예방 범위를 확장할 수 있는 특별한 기회와 함께 HIV PrEP용 레나카파비르(lenacapavir)의 출시를 계획하고 있다. 길리어드는 강력하고 다양한 포트폴리오, 개선된 운영 효율성과 함께 이러한 HIV 분야의 잠재력을 바탕으로 향후 몇 년 동안 환자들에게 더 많은 영향을 미치고 주주들에게 매력적인 수익을 제공할 수 있을 것으로 기대한다.&#8221;
전망: 길리어드는 2025회계연도 조정 주당순이익을 7.70~8.10달러로 예상하며 추정치 7.58달러보다 높았고, 매출은 282억~286억 달러로 예상해 추정치에 부합했다.
GILD 주가 움직임: <a href=""https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw"">Benzinga Pro</a> 데이터에 따르면 길리어드 사이언스 주가는 화요일 애프터마켓에서 4.26% 상승한 100.24달러에 거래되고 있다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 개선되었음을 보여 주었다. 지수는 월요일(10일)에 &#8220;중립&#8221; 구역으로 이동했다.
미국 증시는 월요일 상승 마감했으며, 특히 투자자들이 도널드 트럼프 대통령의 관세 위협을 일축하면서 나스닥 종합지수는 약 1% 상승했다. 칩 제조사들의 주가가 상승했는데 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 2.9% 상승, 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) 4.5% 상승, 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) 3.9% 상승을 나타냈다.
한편, 지난주 미국 증시는 인플레이션과 무역 관세에 대한 우려가 재발하면서 위험 선호도가 줄어들어 하락을 기록했다.
온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) 주가는 회사가 부진한 분기 실적을 발표한 후 8% 이상 하락했다. 맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) 주가는 4분기 실적 발표 후 약 5% 상승했다.
경제지표 측면에서, 미국 소비자 인플레이션 기대치가 1월에 3%로 세 번째 연속적으로 안정세를 보였다.
S&amp;P 500 지수 대부분의 섹터는 상승 마감하였으며, 에너지, 정보기술, 공공서비스 섹터가 상승했다. 그러나 금융과 유틸리티 섹터는 전체 시장 추세와 반대로 하락 마감했다.
다우존스는 월요일에 약 167포인트 상승하여 44,470.41포인트로 마감했고, S&amp;P 500은 0.67% 상승하여 6,066.44포인트, 나스닥 종합은 0.98% 상승하여 19,714.27포인트로 마감했다.
오늘 투자자들은 코카콜라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), 메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), 길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 46.2로 월요일에 &#8220;중립&#8221; 구역으로 이동했다. 이전 지수는 38.8이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Long Ideas

AVGO

NVDA

엔비디아·브로드컴 급등 속 나스닥 1% 상승: 투자 심리 호전, 공포·탐욕 지수는 '중립' 영역으로

화요일(11일) 아침 미국 주식 선물이 하락하고 있는 가운데, 투자자들의 주목을 받을 만한 몇 가지 주식은 다음과 같다.
<ul>
<li>코카콜라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 오늘 개장 전 실적을 발표할 예정이며, 주당순이익 52센트, 매출 106억 8천만 달러가 예상된다. 주식은 애프터 마켓에서 0.1% 상승한 64.63 달러에 거래되었다.</li>
<li>하모닉(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>): 4분기 실적이 예상보다 좋았으나, 1분기 가이던스는 부진하다고 발표했다. 1분기 조정 주당순이익을 2~8센트로 예상되며, 이는 14센트의 예상치에 미치지 못한다. 매출은 1억 2천만~1억 3천 5백만 달러로 예상되며, 이는 1억 5천 4백 76만 달러의 예상치보다 낮다. 주식은 애프터마켓에서 29% 하락한 7.90달러에 거래되었다.</li>
<li>메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>): 오늘 개장 전 실적을 발표할 예정이며 분기 주당순이익이 2.38달러, 매출이 63억 8천만 달러로 예상된다. 주식은 애프터마켓이서  0.3% 하락한 303.51달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>아스테라 랩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>): 4분기 긍정적인 재무 결과를 발표했다. 회사는 1분기 매출을 1억 5천 1백만~1억 5천 5백만 달러로 예상하며, 이는 1억 3천 4백 25만 달러의 예상치보다 높다. 또한 1분기 조정 주당순이익을 28~29센트로 예상한다. 주식은 애프터마켓에서 3.8% 하락한 99.37달러로 거래 되었다.</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): 애널리스트들은 길리어드의 분기별 주당순이익을 1.70달러, 매출을 71억 4천만 달러로 예상한다. 주식은 애프터마켓에서 0.1% 상승한 95.60달러에 거래되었다.</li>
</ul>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ALAB

HLIT

화요일 주목해야 할 주식: 코카콜라, 메리어트, 하모닉, 아스테라 및 길리어드 사이언스

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABBV

ELAN

IDXX

PRGO

REGN

TEVA

VTRS

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

머크 앤드 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 길리어드 사이언스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>)는 주가가 <a href="https://www.benzinga.com/general/health-care">상당히 다른 양상</a>을 보이는 두 제약 대기업이다.
뉴저지주 라웨이에 본사를 둔 머크는 방금 데스 크로스(Death Cross)를 표시하여 앞으로 발생할 수 있는 문제를 예고했다. 반면 캘리포니아주 포스터 시티에 본사를 둔 길리어드는 강세 모멘텀의 신호인 골든 크로스(Golden Cross)를 보여주고 있다.
<h2 class="wp-block-heading">머크: 불안한 상황</h2>
다양한 의약품과 백신 라인업으로 유명한 머크의 주가가 흔들리고 있다. 지난 1년간 8.72%의 괜찮은 상승세에도 불구하고 최근의 기술적 신호는 좋지 않은 모습을 보이고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-527666" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM.png" sizes="(max-width: 639px) 100vw, 639px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM.png 639w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135243/Screenshot-2024-09-03-at-6.05.48-PM-300x214.png 300w" alt="" width="639" height="456" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
우려스러운 데스 크로스—50일 이동 평균선이 200일 이동 평균선을 하향 돌파하는 경우—가 발생하여 약세 추세를 암시하고 있다. 이동평균수렴발산(MACD)가 -0.81로 부정적이고, 상대강도지수(RSI)가 53.93로 과매수 영역에 접어들고 있어 머크는 더 이상 강력한 제약 포트폴리오만으로는 추가 하락을 피하기 어려운 상황이다.
추가 읽기: <a href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data">머크, 두 개의 키트루다 후기 연구 중단 발표</a>
<h2 class="wp-block-heading">길리어드: 골든 웨이브를 타고 상승 중</h2>
반면에 길리어드 사이언스는 상승하고 있다. HIV 및 간염 치료제로 유명한 이 회사는 골든 크로스(Golden Cross)를 경험하고 있으며, 이는 추가 상승 가능성을 암시하는 강세 신호이다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-527668" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM.png" sizes="(max-width: 639px) 100vw, 639px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM.png 639w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/03135357/Screenshot-2024-09-03-at-6.06.11-PM-300x214.png 300w" alt="" width="639" height="456" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
지난달에만 6.82% 상승한 길리어드의 주가는 주요 이동 평균을 훨씬 웃돌았다. MACD는 건강한 1.48, RSI는 68.78로 주가는 강세를 보이고 있지만 투자자들은 과매수 조짐을 주의해야 한다.
<h2 class="wp-block-heading">누가 이길까?</h2>
머크가 약세 추세를 보이는 반면, 길리어드는 상승세를 타고 있다. 투자자들은 이 두 회사의 기술적 신호가 어떻게 다르게 나타나는지를 면밀히 주시할 필요가 있다.
현재로서는 길리어드가 승리한 것으로 보이며, 머크는 주가 회복을 위한 더 강력한 조치가 필요할 것 같다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40419924/gileads-ongoing-battle-against-counterfeit-hiv-medications-persists-with-new-lawsuit-seizes-750k-">길리어드의 가짜 HIV 약물 단속을 위한 지속적인 전투</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Technicals

Signals

머크의 데스 크로스 vs 길리어드의 골든 크로스: 서로 다른 양상을 보이는 두 제약 기업

나스닥 100 지수는 목요일 또 다른 하락세를 보이며 변동성이 심한 세션 이후 6월 초 이후 최저 수준으로 마감했다. 전날 나스닥 100 지수는 3.7% 하락해 <a href="https://www.benzinga.com/markets/equities/24/07/39943580/nasdaq-100-notches-worst-session-since-late-2022-falls-below-key-50-day-moving-average-is-the-ai" target="_blank" rel="noopener" data-google-interstitial="false">2022</a>년 10월 이후 최악의 하락세를 기록했다.
예상보다 높은 2분기 GDP 성장률과 감소하는 물가 압력으로 인해 주식과 위험 자산이 잠시 상승하며 나스닥 100 지수가 뉴욕 정오 거래 중 0.9% 상승했지만, 오후 거래에서는 트레이더들이 연방준비제도(연준)의 금리 인하 베팅을 약간 줄이면서 시장 분위기가 변했다.
오픈AI가 <a href="https://www.benzinga.com/news/24/07/39968522/alphabet-stock-falls-as-openai-plans-searchgpt-what-investors-need-to-know" target="_blank" rel="noopener" data-google-interstitial="false">특정 사용자 그룹</a>에 새로운 검색 기능을 도입하면서 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)은 하락했다.
지난 두 세션 동안 Invesco QQQ Trust(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/qqq" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QQQ" data-google-interstitial="false">QQQ</a>)가 추적하는 나스닥 100 지수는 4.7% 하락하여 2022년 9월 이후 최악의 이틀 하락세를 기록했다.
<h3 class="wp-block-heading">차트: 나스닥 100 지수는 2022년 9월 이후 최악의 2일 하락세</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-457894" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1024x487.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1024x487.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45-1536x731.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/25161029/image-45.png 1920w" alt="" width="1024" height="487" /></figure>
<h3 class="wp-block-heading">목요일 나스닥 100 주식 중 최악의 성과를 낸 10개 주식</h3>
<figure class="wp-block-table is-style-stripes">
<figure class="block core-blockblock core-block table">
<table class="block core-block table">
<tbody>
<tr>
<td>종목</td>
<td>1-Day %</td>
</tr>
<tr>
<td>룰루레몬 애틀라티카(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/lulu" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for LULU" data-google-interstitial="false">LULU</a>)</td>
<td>-9.03%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/wbd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for WBD" data-google-interstitial="false">WBD</a>)</td>
<td>-5.73%</td>
</tr>
<tr>
<td>Arm 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/arm" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ARM">ARM</a>)</td>
<td>-5.45%</td>
</tr>
<tr>
<td>허니웰 인터내셔널(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/hon" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HON">HON</a>)</td>
<td>-5.26%</td>
</tr>
<tr>
<td>어드밴스드 마이크로 디바이시스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/amd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for AMD">AMD</a>)</td>
<td>-4.36%</td>
</tr>
<tr>
<td>부킹 홀딩스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/bkng" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BKNG">BKNG</a>)</td>
<td>-3.86%</td>
</tr>
<tr>
<td>인튜이티브 서지컬(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/isrg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ISRG">ISRG</a>)</td>
<td>-3.79%</td>
</tr>
<tr>
<td>온 세미컨덕터(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/on" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ON">ON</a>)</td>
<td>-3.67%</td>
</tr>
<tr>
<td>덱스콤(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/dxcm" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for DXCM">DXCM</a>)</td>
<td>-3.57%</td>
</tr>
<tr>
<td>퀄컴(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/qcom" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for QCOM">QCOM</a>)</td>
<td>-3.15%</td>
</tr>
<tr>
<td>알파벳(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/googl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for GOOGL">GOOGL</a>)</td>
<td>-3.07%</td>
</tr>
</tbody>
</table>
</figure>
</figure>
<h3 class="wp-block-heading">목요일 나스닥 100 주식 중 최고의 성과를 낸 5개 주식</h3>
<figure class="wp-block-table is-style-stripes">
<figure class="block core-blockblock core-block table">
<table class="block core-block table">
<tbody>
<tr>
<td>종목</td>
<td>1-Day %</td>
</tr>
<tr>
<td>아틀라시안(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/team" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TEAM">TEAM</a>)</td>
<td>6.34%</td>
</tr>
<tr>
<td>올드 도미니언 프레이트 라인(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/odfl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ODFL">ODFL</a>)</td>
<td>5.74%</td>
</tr>
<tr>
<td>몽고DB(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/mdb" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MDB">MDB</a>)</td>
<td>4.83%</td>
</tr>
<tr>
<td>길리어드 사이언시스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" style="font-family: inherit; font-size: inherit; font-weight: inherit;" href="https://www.benzinga.com/quote/gild" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for GILD">GILD</a>)</td>
<td>4.12%</td>
</tr>
<tr>
<td>오릴리 오토모티브(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/orly" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ORLY">ORLY</a>)</td>
<td>4.09%</td>
</tr>
</tbody>
</table>
</figure>
</figure>
<h3></h3>
Photo via Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Sector ETFs

Tech

BKNG

DXCM

GOOG

GOOGL

ISRG

LULU

MTTR

ODFL

ORLY

QCOM

TEAM

나스닥 100 지수는 거의 2년 만에 최악의 2일 하락폭을 기록하며  7주 만에 최저치

이들 대형주들은 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>사렙타 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)의 주가는 회사가 엘리비디스(ELEVIDYS)의 라벨 표시 적응증에 최소 4세 이상의 듀센 <span class="c5aZPb" tabindex="0" role="button" data-enable-toggle-animation="true" data-extra-container-classes="ZLo7Eb" data-hover-hide-delay="1000" data-hover-open-delay="500" data-send-open-event="true" data-theme="0" data-width="250" data-ved="2ahUKEwijqpmq3vKGAxXva_UHHc50CRoQmpgGegQIERAD">근이영양증(DMD) 유전자 돌연변이가 확인된 듀센 근이영양증 환자를 포함하도록 확장하는 것에 대한 미 식품의약국(FDA)의 승인을 발표한 후 29.50% 상승했다. 또한, 여러 투자 은행들이 해당 종목에 대해 <a href="https://www.benzinga.com/quote/srpt/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 목표 주가를 상향 조정</a>했다.</li>
<li>시리우스 XM 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)의 주가는 지난주 16.73% 상승했다.</li>
<li>토스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)의 주가는 지난주 15.57% 상승했다.</li>
<li>길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)의 주가는 <a href="https://www.benzinga.com//node/39435732" target="_blank" rel="noreferrer noopener">긍정적인 3단계 HIV 데이터</a> 이후 지속적인 강세를 보이며 지난주 12.62% 상승했다.</li>
<li>츄이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)의 주가는 10.59% 상승했다. 이는 5월 <a href="https://www.benzinga.com//node/39385252" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">o온라인 매장에서의 소매 구매가 증가</a>한 후 주가가 올랐을 가능성이 크다.</li>
<li>액센츄어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>)의 회사가 3분기 실적을 <a href="https://www.benzinga.com//node/39410240" target="_blank" rel="noreferrer noopener">발표한 이후</a> 주가는 9.80% 상승했다. 몇몇 분석가들은 가격 예측을 <a href="https://www.benzinga.com/quote/acn/analyst-ratings" target="_blank" rel="noreferrer noopener">하향 조정</a>했습니다.</li>
<li>드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)의 주가는 지난주 9.69% 상승했다. 이는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">6월 30일까지 최종 확정되어야 할 뉴저지 2025년 예산안에 세금을 도입하지 않을 것으로 예상되어, 플로리다의 온라인 스포츠 베팅의 미래에 중대한 영향을 미칠 결정에 따른 주가 상승으로 보입니다.</a></li>
<li>이러한 급증은 플로리다 온라인 스포츠 베팅의 미래에 중요한 영향을 미치는 미국 대법원의 중추적 결정과 6월 30일까지 확정되어야 하는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39316935/draftkings-stock-can-overcome-wall-of-worry-around-various-regulatory-risks-analyst">뉴저지의 2025년 예산에 세금</a>이 도입되지 않을 것이라는 낙관론에 따른 것이다.</li>
<li>델(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)의 주가는 일론 머스크가 회사의 xAI가 구축하고 있는 슈퍼컴퓨터에 들어갈 이 랙의 절반을 조립하고 있다고 <a href="http://dell%20shares%20are%20trading%20higher%20after%20elon%20musk%20said%20the%20company%20is%20assembling%20half%20of%20the%20racks%20that%20are%20going%20into%20the%20supercomputer%20that%20xai%20is%20building./" target="_blank" rel="noopener">말한</a> 후 지난주 8.19% 상승했다.</li>
<li>오토데스크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>)의 주가는 스타보드(Starboard)가 이 회사의 지분을 5억 달러 보유하고 있다고 <a href="https://www.benzinga.com//node/39357211">보도된 이후</a> 7.99% 상승했다.</li>
<li>골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주가는 7.15% 상승했다. <a href="https://www.benzinga.com//node/39416585" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">금값 상승 속</a>에 금 광산주 주가가 상승세를 보이고 있다.</li>
</ol>
사진제공: 셔터스톡
다음 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

Gilead Sciences

뉴스

에 대한 최신 뉴스 Gilead Sciences (NASDAQ:GILD) 주식

금요일, 3월 07, 2025

수요일, 2월 12, 2025

화요일, 2월 11, 2025

월요일, 12월 23, 2024

화요일, 9월 03, 2024

목요일, 7월 25, 2024

일요일, 6월 23, 2024

토요일, 6월 22, 2024

화요일, 4월 09, 2024

월요일, 4월 01, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌